EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML)
- HS-10382, as monotherapy and in combination with Flumatinib, has shown promising anti-tumor activity with a generally manageable safety profile in t...
2026.06.12